<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070522</url>
  </required_header>
  <id_info>
    <org_study_id>REB1000053825</org_study_id>
    <nct_id>NCT03070522</nct_id>
  </id_info>
  <brief_title>Prednisone in Cystic Fibrosis Pulmonary Exacerbations</brief_title>
  <acronym>PIPE</acronym>
  <official_title>Randomized Controlled Trial of Prednisone in Cystic Fibrosis Pulmonary Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a 5 year randomized, double blind, placebo controlled trial of 7 days of oral&#xD;
      prednisone in cystic fibrosis (CF) patients receiving intravenous (IV) antibiotic treatment&#xD;
      for a pulmonary exacerbation at the Hospital for Sick Children and other study sub-sites&#xD;
      across Canada. The intervention will be oral prednisone 2 mg/kg/day (max 60 mg) divided twice&#xD;
      daily for 7 days as an adjunctive therapy for pulmonary exacerbations in CF patients who have&#xD;
      not recovered their baseline forced expiratory volume in 1 second (FEV1) after 7 days of IV&#xD;
      antibiotic treatment. The primary outcome will be the proportion of subjects who achieve &gt;90%&#xD;
      of their baseline FEV1 % predicted at day 14 of IV antibiotic treatment for a pulmonary&#xD;
      exacerbation in each treatment arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lung function recovery</measure>
    <time_frame>At 14 days of antibiotic therapy</time_frame>
    <description>The proportion of subjects who achieve &gt;90% of their baseline FEV1 % predicted at day 14 of IV antibiotic treatment for a PEx in each treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung function recovery at follow up visit</measure>
    <time_frame>1 month follow up</time_frame>
    <description>The proportion of subjects who achieve &gt;90% of their baseline FEV1 % predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in pulmonary function testing</measure>
    <time_frame>at day 7, 14 and 1 month follow up</time_frame>
    <description>change in pulmonary function testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life as measured by CFQ-R questionnaire</measure>
    <time_frame>at day 7, 14 and 1 month follow up</time_frame>
    <description>quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life as measured by CF Respiratory Symptom Diary</measure>
    <time_frame>at day 7, 14 and 1 month follow up</time_frame>
    <description>quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospitalization</measure>
    <time_frame>Through study completion, up to 100 weeks</time_frame>
    <description>length of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to subsequent pulmonary exacerbation</measure>
    <time_frame>1 year follow up time</time_frame>
    <description>time to subsequent pulmonary exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>At day day 14 of antibiotic therapy and 1 month follow up</time_frame>
    <description>number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in sputum inflammatory markers</measure>
    <time_frame>at day 7, 14 and 1 month follow up</time_frame>
    <description>change in sputum inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum inflammatory markers</measure>
    <time_frame>at day 7, 14 and 1 month follow up</time_frame>
    <description>change in serum inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment</measure>
    <time_frame>Through study completion, up to 100 weeks</time_frame>
    <description>Duration of antibiotic treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Cystic Fibrosis Pulmonary Exacerbation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>oral prednisone for 7 days during pulmonary exacerbation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of CF by newborn screening or at least one clinical feature of CF, AND&#xD;
             either (a) or (b) as follows:&#xD;
&#xD;
          2. A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis&#xD;
&#xD;
          3. A genotype with two identifiable CF-causing mutations&#xD;
&#xD;
          4. Age &gt; 6 years old.&#xD;
&#xD;
          5. Acute pulmonary exacerbation treated with IV antibiotics as previously defined 10%&#xD;
             relative drop in FEV1 from baseline at the time of exacerbation&#xD;
&#xD;
          6. Informed consent by patient or parent/legal guardian&#xD;
&#xD;
          7. Ability to reproducibly perform pulmonary function testing&#xD;
&#xD;
          8. Ability to comply with medication use including the ability to take capsules, study&#xD;
             visits and study procedures as judged by the site investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A respiratory tract culture positive for Burkholderia cenocepacia in the 12 months&#xD;
             prior to enrollment&#xD;
&#xD;
          2. A respiratory tract culture positive for Mycobacterium abscessus in the 12 months&#xD;
             prior to enrollment&#xD;
&#xD;
          3. Treatment with IV or oral corticosteroids within 2 weeks of enrollment or from Day&#xD;
             0-Day 7 of the pulmonary exacerbation&#xD;
&#xD;
          4. Active allergic bronchopulmonary aspergillosis (ABPA) at the time of enrollment as&#xD;
             determined by treating physician&#xD;
&#xD;
          5. Asthma related exacerbation at enrollment as defined by the treating physician based&#xD;
             on clinically compatible symptoms (eg. wheeze)&#xD;
&#xD;
          6. History of avascular necrosis or pathologic bone fracture&#xD;
&#xD;
          7. Uncontrolled hypertension with end organ damage&#xD;
&#xD;
          8. Active gastrointestinal bleeding&#xD;
&#xD;
          9. Status post lung or other organ transplantation&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. Lactose intolerance (contained in placebo)&#xD;
&#xD;
         12. On Lumacaftor-Ivacaftor (Orkambi) at the time of exacerbation&#xD;
&#xD;
         13. Investigational drug use within 30 days prior to enrollment visit&#xD;
&#xD;
         14. Physical findings that would compromise the safety of the subject or the quality of&#xD;
             the study data as determined by site investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valerie Waters, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>204541</phone_ext>
    <email>valerie.waters@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amara Mathews</last_name>
    <email>amara.mathews@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Governers of The University of Calgary - Alberta Health Services</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Smith</last_name>
      <email>Clare.Smith@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Parkins, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Sandoval</last_name>
      <email>Rodrigo.Sandoval@bcchr.ca</email>
    </contact>
    <investigator>
      <last_name>Jonathan Rayment, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekjot Sangha</last_name>
      <email>esangha@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Bradley Quon, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2R5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Fleishcer</last_name>
      <email>Erin.Fleischer@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>April Price, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bashour Yazji</last_name>
      <email>byazji@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Seguin</last_name>
      <email>iseguin@toh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Melanie Chin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Health Toronto - St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamalprit Chokar</last_name>
      <email>Kamalprit.Chokar@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Tullis, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SickKids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Waters</last_name>
      <phone>416-813-7654</phone>
      <email>valerie.waters@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Amara Mathews</last_name>
      <email>amara.mathews@sickkids.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X A09</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Cote-Maurais</last_name>
      <email>guillaume.cote-maurais.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Annick Lavoie, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Robert</last_name>
      <email>nora.robert.hsj@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Sze Man Tse, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Desnoyers</last_name>
      <email>gabrielle.desnoyers@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Patrick Daigneault, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andree-Anne Therrien</last_name>
      <email>andree-anne.therrien@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Vadeboncoeur</last_name>
      <email>nathalie.vadeboncoeur@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Lara Bilodeau, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan - Saskatchewan Health Authority</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Johnson</last_name>
      <email>dawn.johnson@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Julian Tam, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Valerie Waters</investigator_full_name>
    <investigator_title>Staff physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

